Prolonged survival after small-cell transformation of EGFR-mutant lung adenocarcinoma: a case report
- 1Department of Oncology, Hebei General Hospital, Shijiazhuang
- 2Vascular Surgery Catheterization Room, Hebei General Hospital, Shijiazhuang
Abstract
Transformed small cell lung cancer (T-SCLC) is most commonly observed in EGFR-mutant lung adenocarcinoma and represents an important mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Its reported clinical incidence is approximately 3%-10%. Patients with T-SCLC often experience rapid disease progression and poor overall prognosis, and no established standard treatment regimen is currently available. We report a case of advanced EGFR-mutant lung adenocarcinoma with RB1 , TP53 , and BRCA2 co-mutations that underwent small-cell transformation during treatment. Small-cell transformation was detected through close surveillance and confirmed by repeat biopsy. The patient subsequently received individualized multimodal therapy, including chemotherapy, targeted therapy, and local radiotherapy, and remained alive 43 months after the initial diagnosis.
Related
- Transformation to Small‐Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR‐Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report
- Case report and literature review: histologic transformation from EGFR-mutant lung adenocarcinoma to squamous cell carcinoma with newly detected SMAD4 and ATM variants
- Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR-mutant Lung Adenocarcinoma
- Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer
- Early disease control with a biochemical response to aumolertinib after postoperative recurrence of EGFR-Mutant stage IIIA lung adenocarcinoma after icotinib, with EGFR T790M detected at recurrence: a Case Report
BibTeX
@article{yan2026prolonged,
title = {{Prolonged survival after small-cell transformation of EGFR-mutant lung adenocarcinoma: a case report}},
author = {Yaxin Yan and Dongjie Du and Fenghua Wen and Jiaqi Wang and Yitao Jia},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1975965},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1975965/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prolonged survival after small-cell transformation of EGFR-mutant lung adenocarcinoma: a case report
AU - Yaxin Yan
AU - Dongjie Du
AU - Fenghua Wen
AU - Jiaqi Wang
AU - Yitao Jia
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1975965
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1975965/full
AB - Transformed small cell lung cancer (T-SCLC) is most commonly observed in EGFR-mutant lung adenocarcinoma and represents an important mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Its reported clinical incidence is approximately 3%-10%. Patients with T-SCLC often experience rapid disease progression and poor overall prognosis, and no established standard treatment regimen is currently available. We report a case of advanced EGFR-mutant lung adenocarcinoma with RB1 , TP53 , and BRCA2 co-mutations that underwent small-cell transformation during treatment. Small-cell transformation was detected through close surveillance and confirmed by repeat biopsy. The patient subsequently received individualized multimodal therapy, including chemotherapy, targeted therapy, and local radiotherapy, and remained alive 43 months after the initial diagnosis.
SN - 2234-943X
ER -